Panmira Announces Appointment of New CEO

Panmira Announces Appointment of New CEO

SAN DIEGO, Oct. 17, 2011 /PRNewswire via COMTEX/ -- Panmira Pharmaceuticals, LLC, today announced the appointment of Hari Kumar, PhD, as chief executive officer. Until recently, Dr. Kumar served as chief business officer of Amira Pharmaceuticals Inc. and led the transaction with Bristol-Myers Squibb Inc. for the sale of Amira's fibrosis program.

Dr. Kumar and his team will oversee efforts on Panmira's inflammation portfolio, which features a best-in-class CRTH2 program. The lead candidate, AM211, represents one of the most promising compounds in the field, having demonstrated 100 percent functional inhibition of eosinophils over 24 hours following oral, once-daily dosing in phase I studies. CRTH2 antagonists show promise for several diseases including eosinophilic esophagitis, eosinophilic asthma, COPD, and atopic dermatitis, and represent a new class of therapy for these under-served markets.

About Panmira

Founded in 2011 and headquartered in San Diego, Panmira is a small molecule pharmaceutical company focused on novel therapies for inflammatory diseases. Panmira was spun out of Amira Pharmaceuticals prior to Amira's acquisition by Bristol-Myers Squibb. Investors include Dr. Brad Bolzon (Versant Ventures), Mr. Kevin Kinsella (Avalon Ventures), Dr. David Schnell (Prospect Venture Partners) and Dr. Heath Lukatch (Novo A/S).

For more information, visit .

SOURCE Panmira Pharmaceuticals, LLC


Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.